Pharmacological Strategies in Lung Cancer-Induced Cachexia: Effects on Muscle Proteolysis, Autophagy, Structure, and Weakness

Journal of Cellular Physiology

Volumn 229, Issue 11, 2014, Pages 1660-1672

  Chacon Cabrera, Alba ^a,b   Fermoselle, Clara ^a,b   Urtreger, Alejandro J ^c   Mateu Jimenez, Mercè ^a,b   Diament, Miriam J ^c   de Kier Joffé, Elisa D Bal ^c   Sandri, Marco ^d   Barreiro, Esther ^a,b  

^a Barcelona Biomedical Research Park   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYOGENIN; MYOSTATIN; PROTEASOME; SALAZOSULFAPYRIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BODY WEIGHT; CACHEXIA; CONTROLLED STUDY; DIAPHRAGM; GASTROCNEMIUS MUSCLE; HUMAN; HUMAN CELL; INFLAMMATION; LUNG CANCER; MOUSE; MUSCLE MASS; MUSCLE STRENGTH; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; WEAKNESS;

ANIMALS; AUTOPHAGY; BORONIC ACIDS; BUTADIENES; CACHEXIA; CELL LINE, TUMOR; INFLAMMATION; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MUSCLE CONTRACTION; MUSCLE PROTEINS; MUSCLE WEAKNESS; MUSCLE, SKELETAL; NF-KAPPA B; NITRILES; OXIDATION-REDUCTION; PROTEOLYSIS; PYRAZINES; SIGNAL TRANSDUCTION; SULFASALAZINE; TYROSINE; WEIGHT GAIN;

EID: 84904910803     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24611     Document Type: Article

References (62)

1. Agusti A, Morla M, Sauleda J, Saus C, Busquets X. 2004. NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax 59:483-487.
2. Alger HM, Raben N, Pistilli E, Francia DL, Rawat R, Getnet D, Ghimbovschi S, Chen YW, Lundberg IE, Nagaraju K. 2011. The role of TRAIL in mediating autophagy in myositis skeletal muscle: A potential nonimmune mechanism of muscle damage. Arthritis Rheum 63:3448-3457.
3. Argiles JM, Busquets S, Lopez-Soriano FJ. 2011. Anti-inflammatory therapies in cancer cachexia. Eur J Pharmacol 668:S81-S86.
4. Argiles JM, Lopez-Soriano FJ. 1996. The ubiquitin-dependent proteolytic pathway in skeletal muscle: Its role in pathological states. Trends Pharmacol Sci 17:223-226.
5. Aversa Z, Bonetto A, Penna F, Costelli P, Di 2012. RG, Lacitignola A, Baccino FM, Ziparo V, Mercantini P, Rossi FF, Muscaritoli M. Changes in myostatin signaling in non-weight-losing cancer patients. Ann Surg Oncol 19:1350-1356.
6. Barreiro E, de la PB, Busquets S, Lopez-Soriano FJ, Gea J, Argiles JM. 2005. Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Lett 579:1646-1652.
7. Barreiro E, Del Puerto-Nevado L, Puig-Vilanova E, Perez-Rial S, Sanchez F, Martinez-Galan L, Rivera S, Gea J, Gonzalez-Mangado N, Peces-Barba G. 2012. Cigarette smoke-induced oxidative stress in skeletal muscles of mice. Respir Physiol Neurobiol 182:9-17.
8. Barreiro E, Ferrer D, Sanchez F, Minguella J, Marin-Corral J, Martinez-Llorens J, Lloreta J, Gea J. 2011. Inflammatory cells and apoptosis in respiratory and limb muscles of patients with COPD. J Appl Physiol 111:808-817.
9. Barreiro E, Garcia-Martinez C, Mas S, Ametller E, Gea J, Argiles JM, Busquets S, Lopez-Soriano FJ. 2009. UCP3 overexpression neutralizes oxidative stress rather than nitrosative stress in mouse myotubes. FEBS Lett 583:350-356.
10. Barreiro E, Marin-Corral J, Sanchez F, Mielgo V, Alvarez FJ, Galdiz JB, Gea J. 2010. Reference values of respiratory and peripheral muscle function in rats. J Anim Physiol Anim Nutr (Berl) 94:e393-e401.
11. Barreiro E, Peinado VI, Galdiz JB, Ferrer E, Marin-Corral J, Sanchez F, Gea J, Barbera JA. 2010. Cigarette smoke-induced oxidative stress: A role in chronic obstructive pulmonary disease skeletal muscle dysfunction. Am J Respir Crit Care Med 182:477-488.
12. Barreiro E, Schols AM, Polkey MI, Galdiz JB, Gosker HR, Swallow EB, Coronell C, Gea J. 2008. Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax 63:100-107.
13. Busquets S, Toledo M, Orpi M, Massa D, Porta M, Capdevila E, Padilla N, Frailis V, Lopez-Soriano FJ, Han HQ, Argiles JM. 2012. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachexia Sarcopenia Muscle 3:37-43.
14. Cai D, Frantz JD, Tawa NE, Jr., Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE. 2004. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119:285-298.
15. Camara-Lemarroy CR, Guzman-de la Garza FJ, Alarcon-Galvan G, Cordero-Perez P, Fernandez-Garza NE. 2009. Effect of sulfasalazine on renal ischemia/reperfusion injury in rats. Ren Fail 31:822-828.
16. Cvek B, Dvorak Z. 2007. Targeting of nuclear factor-kappaB and proteasome by dithiocarbamate complexes with metals. Curr Pharm Des 13:3155-3167.
17. Diament MJ, Garcia C, Stillitani I, Saavedra VM, Manzur T, Vauthay L, Klein S. 1998. Spontaneous murine lung adenocarcinoma (P07): A new experimental model to study paraneoplastic syndromes of lung cancer. Int J Mol Med 2:45-50.
18. Diament MJ, Peluffo GD, Stillitani I, Cerchietti LC, Navigante A, Ranuncolo SM, Klein SM. 2006. Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin. Cancer Invest 24:126-131.
19. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi FF, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD. 2008. Cachexia: A new definition. Clin Nutr 27:793-799.
20. Fareed MU, Evenson AR, Wei W, Menconi M, Poylin V, Petkova V, Pignol B, Hasselgren PO. 2006. Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression. Am J Physiol Regul Integr Comp Physiol 290:R1589-R1597.
21. Fermoselle C, Rabinovich R, Ausin P, Puig-Vilanova E, Coronell C, Sanchez F, Roca J, Gea J, Barreiro E. 2012. Does oxidative stress modulate limb muscle atrophy in severe COPD patients?. Eur Respir J 40:851-862.
22. Fermoselle C, Sanchez F, Barreiro E. 2011. Reduction of muscle mass mediated by myostatin in an experimental model of pulmonary emphysema. Arch Bronconeumol 47:590-598.
23. Ferraro E, Giammarioli AM, Caldarola S, Lista P, Feraco A, Tinari A, Salvatore AM, Malorni W, Berghella L, Rosano G. 2013. The metabolic modulator trimetazidine triggers autophagy and counteracts stress-induced atrophy in skeletal muscle myotubes. FEBS J 280:5094-5108.
24. Garcia JM, Scherer T, Chen JA, Guillory B, Nassif A, Papusha V, Smiechowska J, Asnicar M, Buettner C, Smith RG. 2013. Inhibition of cisplatin-induced lipid catabolism and weight loss by ghrelin in male mice. Endocrinology 154:3118-3129.
25. Hajjaji N, Couet C, Besson P, Bougnoux P. 2012. DHA effect on chemotherapy-induced body weight loss: An exploratory study in a rodent model of mammary tumors. Nutr Cancer 64:1000-1007.
26. Kramer HF, Goodyear LJ. 2007. Exercise, MAPK, and NF-kappaB signaling in skeletal muscle. J Appl Physiol 103:388-395.
27. Lu C, Gallegos R, Li P, Xia CQ, Pusalkar S, Uttamsingh V, Nix D, Miwa GT, Gan LS. 2006. Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos 34:702-708.
28. Marin-Corral J, Fontes CC, Pascual-Guardia S, Sanchez F, Olivan M, Argiles JM, Busquets S, Lopez-Soriano FJ, Barreiro E. 2010. Redox balance and carbonylated proteins in limb and heart muscles of cachectic rats. Antioxid Redox Signal 12:365-380.
29. Mastrocola R, Reffo P, Penna F, Tomasinelli CE, Boccuzzi G, Baccino FM, Aragno M, Costelli P. 2008. Muscle wasting in diabetic and in tumor-bearing rats: role of oxidative stress. Free Radic Biol Med 44:584-593.
30. McClung JM, Judge AR, Powers SK, Yan Z. 2010. P38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. Am J Physiol Cell Physiol 298:C542-C549.
31. Moore-Carrasco R, Busquets S, Almendro V, Palanki M, Lopez-Soriano FJ, Argiles JM. 2007. The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. Int J Oncol 30:1239-1245.
32. Morley JE, Argiles JM, Evans WJ, Bhasin S, Cella D, Deutz NE, Doehner W, Fearon KC, Ferrucci L, Hellerstein MK, Kalantar-Zadeh K, Lochs H, MacDonald N, Mulligan K, Muscaritoli M, Ponikowski P, Posthauer ME, Rossi FF, Schambelan M, Schols AM, Schuster MW, Anker SD. 2010. Nutritional recommendations for the management of sarcopenia. J Am Med Dir Assoc 11:391-396.
33. Murphy KT, Chee A, Trieu J, Naim T, Lynch GS. 2012. Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia. Dis Model Mech 5:533-545.
34. Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi FF. 2006. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 42:31-41.
35. Olmez D, Babayigit A, Uzuner N, Erbil G, Karaman O, Yilmaz O, Cetin EO, Ozogul C. 2008. Efficacy of sulphasalazine on lung histopathology in a murine model of chronic asthma. Exp Lung Res 34:501-511.
36. Penna F, Costamagna D, Fanzani A, Bonelli G, Baccino FM, Costelli P. 2010. Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One 5:e13604.
37. Penner CG, Gang G, Wray C, Fischer JE, Hasselgren PO. 2001. The transcription factors NF-kappab and AP-1 are differentially regulated in skeletal muscle during sepsis. Biochem Biophys Res Commun 281:1331-1336.
38. Peterson JM, Bakkar N, Guttridge DC. 2011. NF-kappaB signaling in skeletal muscle health and disease. Curr Top Dev Biol 96:85-119.
39. Powers SK, Kavazis AN, DeRuisseau KC. 2005. Mechanisms of disuse muscle atrophy: role of oxidative stress. Am J Physiol Regul Integr Comp Physiol 288:R337-R344.
40. Robert F, Mills JR, Agenor A, Wang D, DiMarco S, Cencic R, Tremblay ML, Gallouzi IE, Hekimi S, Wing SS, Pelletier J. 2012. Targeting protein synthesis in a Myc/mTOR-driven model of anorexia-cachexia syndrome delays its onset and prolongs survival. Cancer Res 72:747-756.
41. Roberts BM, Ahn B, Smuder AJ, Al-Rajhi M, Gill LC, Beharry AW, Powers SK, Fuller DD, Ferreira LF, Judge AR. 2013. Diaphragm and ventilatory dysfunction during cancer cachexia. FASEB J 27:2600-2610.
42. Roth GA, Moser B, Krenn C, Roth-Walter F, Hetz H, Richter S, Brunner M, Jensen-Jarolim E, Wolner E, Hoetzenecker K, Boltz-Nitulescu G, Ankersmit HJ. 2005. Heightened levels of circulating 20S proteasome in critically ill patients. Eur J Clin Invest 35:399-403.
43. Rui T, Kvietys PR. 2005. NFkappaB and AP-1 differentially contribute to the induction of Mn-SOD and eNOS during the development of oxidant tolerance. FASEB J 19:1908-1910.
44. Schuh K, Pahl A. 2009. Inhibition of the MAP kinase ERK protects from lipopolysaccharide-induced lung injury. Biochem Pharmacol 77:1827-1834.
45. Smith HJ, Tisdale MJ. 2003. Signal transduction pathways involved in proteolysis-inducing factor induced proteasome expression in murine myotubes. Br J Cancer 89:1783-1788.
46. Sundaramoorthy S, Ryu MS, Lim IK. 2013. B-cell translocation gene 2 mediates crosstalk between PI3K/Akt1 and NFkappaB pathways which enhances transcription of MnSOD by accelerating IkappaBalpha degradation in normal and cancer cells. Cell Commun Signal 11:69.
47. Supinski GS, Callahan LA. 2006. Caspase activation contributes to endotoxin-induced diaphragm weakness. J Appl Physiol 100:1770-1777.
48. Supinski GS, Vanags J, Callahan LA. 2009. Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction. Am J Physiol Lung Cell Mol Physiol 296:L994-L1001.
49. Testelmans D, Crul T, Maes K, Agten A, Crombach M, Decramer M, Gayan-Ramirez G. 2010. Atrophy and hypertrophy signalling in the diaphragm of patients with COPD. Eur Respir J 35:549-556.
50. Tischler ME, Desautels M, Goldberg AL. 1982. Does leucine, leucyl-tRNA, or some metabolite of leucine regulate protein synthesis and degradation in skeletal and cardiac muscle?. J Biol Chem 257:1613-1621.
51. Toledo M, Busquets S, Sirisi S, Serpe R, Orpi M, Coutinho J, Martinez R, Lopez-Soriano FJ, Argiles JM. 2011. Cancer cachexia: physical activity and muscle force in tumour-bearing rats. Oncol Rep 25:189-193.
52. Troosters T, Probst VS, Crul T, Pitta F, Gayan-Ramirez G, Decramer M, Gosselink R. 2010. Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181:1072-1077.
53. Urtreger AJ, Diament MJ, Ranuncolo SM, Del CV, Puricelli LI, Klein SM, De Kier Joffe ED. 2001. New murine cell line derived from a spontaneous lung tumor induces paraneoplastic syndromes. Int J Oncol 18:639-647.
54. van Hees HW, Li YP, Ottenheijm CA, Jin B, Pigmans CJ, Linkels M, Dekhuijzen PN, Heunks LM. 2008. Proteasome inhibition improves diaphragm function in congestive heart failure rats. Am J Physiol Lung Cell Mol Physiol 294:L1260-L1268.
55. van HH, Ottenheijm C, Ennen L, Linkels M, Dekhuijzen R, Heunks L. 2011. Proteasome inhibition improves diaphragm function in an animal model for COPD. Am J Physiol Lung Cell Mol Physiol 301:L110-L116.
56. Vignaud A, Ferry A, Huguet A, Baraibar M, Trollet C, Hyzewicz J, Butler-Browne G, Puymirat J, Gourdon G, Furling D. 2010. Progressive skeletal muscle weakness in transgenic mice expressing CTG expansions is associated with the activation of the ubiquitin-proteasome pathway. Neuromuscul Disord 20:319-325.
57. Vogiatzis I, Simoes DC, Stratakos G, Kourepini E, Terzis G, Manta P, Athanasopoulos D, Roussos C, Wagner PD, Zakynthinos S. 2010. Effect of pulmonary rehabilitation on muscle remodelling in cachectic patients with COPD. Eur Respir J 36:301-310.
58. von HS, Anker SD. 2010. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 1:1-5.
59. Wahl C, Liptay S, Adler G, Schmid RM. 1998. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101:1163-1174.
60. Whittemore LA, Song K, Li X, Aghajanian J, Davies M, Girgenrath S, Hill JJ, Jalenak M, Kelley P, Knight A, Maylor R, O'Hara D, Pearson A, Quazi A, Ryerson S, Tan XY, Tomkinson KN, Veldman GM, Widom A, Wright JF, Wudyka S, Zhao L, Wolfman NM. 2003. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 300:965-971.
61. Xue H, Sawyer MB, Wischmeyer PE, Baracos VE. 2011. Nutrition modulation of gastrointestinal toxicity related to cancer chemotherapy: from preclinical findings to clinical strategy. JPEN J Parenter Enteral Nutr 35:74-90.
62. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, Lacey DL, Goldberg AL, Han HQ. 2010. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142:531-543.